A detailed history of Jpmorgan Chase & CO transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 52,840 shares of TNGX stock, worth $215,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,840
Previous 51,559 2.48%
Holding current value
$215,587
Previous $442,000 8.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$7.36 - $11.93 $9,428 - $15,282
1,281 Added 2.48%
52,840 $406,000
Q2 2024

Aug 12, 2024

SELL
$6.66 - $10.15 $473,779 - $722,050
-71,138 Reduced 57.98%
51,559 $442,000
Q1 2024

May 10, 2024

BUY
$7.51 - $12.88 $547,433 - $938,874
72,894 Added 146.36%
122,697 $974,000
Q4 2023

Feb 12, 2024

BUY
$6.52 - $12.01 $16,632 - $30,637
2,551 Added 5.4%
49,803 $493,000
Q3 2023

Nov 14, 2023

BUY
$2.93 - $11.26 $22,338 - $85,846
7,624 Added 19.24%
47,252 $532,000
Q2 2023

Aug 11, 2023

SELL
$2.67 - $4.7 $56,980 - $100,302
-21,341 Reduced 35.0%
39,628 $131,000
Q1 2023

May 18, 2023

BUY
$3.76 - $8.06 $213,436 - $457,525
56,765 Added 1350.26%
60,969 $240,000
Q1 2023

May 11, 2023

SELL
$3.76 - $8.06 $172,151 - $369,027
-45,785 Reduced 91.59%
4,204 $16,000
Q4 2022

Feb 13, 2023

BUY
$3.41 - $8.29 $27,736 - $67,430
8,134 Added 19.43%
49,989 $363,000
Q3 2022

Nov 14, 2022

SELL
$3.25 - $5.46 $24,284 - $40,797
-7,472 Reduced 15.15%
41,855 $151,000
Q2 2022

Aug 11, 2022

BUY
$3.86 - $8.01 $89,127 - $184,950
23,090 Added 88.01%
49,327 $224,000
Q1 2022

May 11, 2022

SELL
$7.01 - $10.94 $44,148 - $68,900
-6,298 Reduced 19.36%
26,237 $199,000
Q4 2021

Feb 10, 2022

BUY
$9.55 - $14.29 $293,404 - $439,031
30,723 Added 1695.53%
32,535 $357,000
Q3 2021

Nov 12, 2021

BUY
$9.56 - $17.3 $17,322 - $31,347
1,812 New
1,812 $23,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $359M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.